CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Results of Operations and Financial ConditionItem 2.02.Results of Operations and Financial Condition.
CytRx Corporation on August 3, 2017 issued a press release regarding its financial results for the quarter ended June 30, 2017. A copy of the press release is attached as Exhibit 99 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
The exhibit listed on the accompanying Index to Exhibits is filed herewith.
CYTRX CORP ExhibitEX-99 2 exh99.htm EARNINGS PRESS RELEASE DATED AUGUST 3,…To view the full exhibit click here
About CYTRX CORPORATION (NASDAQ:CYTR)
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
